PET scan for cancers with high HER2 levels
Part of Cancer clinical trials.
This study is testing a new type of PET scan that uses a special molecule (68Ga-Her2-affibody) to find tumors that have high levels of HER2. It may help doctors better see where your cancer is and decide on the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you have cancer, or your doctor strongly suspects it.
- Your cancer is known to have high levels of HER2 protein (HER2-positive).
- You can read and sign a consent form agreeing to be in the study.
- You are at least 18 years old (implied).
- You are able to have a PET scan (no medical reasons preventing it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
This trial studies an imaging tracer that targets HER2, a protein that can be found in certain cancers. It may help doctors see where HER2-positive tumors are in the body using scans.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.